Mary-Elizabeth Gifford
As the Chief of Global Impact for Clearmind Medicine, Mary-Elizabeth Gifford works to build bridges between research, regulation, and patient care to accelerate the development of responsible regulated psychedelic medicines to treat previously intractable medical conditions. Prior to joining Clearmind, Gifford served as Chief of Global Impact at Psyence BioMed, a Nasdaq-listed biopharmaceutical company with a focus on nature-derived psychedelic medicine. In 2020 Gifford joined Psyence, Psyence BioMed's associated CSE-listed company, from the D.C.-based non-profit Center for Mind-Body Medicine, where she led public policy. Educated at Brown University with a post-grad year of study at Harvard, she is co-author of the Nature vs. Synthetic Psilocybin chapter in the recently published Springer Nature textbook on therapeutic mushrooms and she regularly publishes on psychedelic policy issues; her original research has been cited by the Journal of the American Academy of Psychotherapists and elsewhere. Gifford is chair of the non-profit Global Wellness Institute's Psychedelics & Healing Initiative; Spirituality & Health Magazine describes her as "the most quietly influential woman working in psychedelics today.” Gifford lives in New York City and Washington, D.C.
